Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

CompletedOBSERVATIONAL
Enrollment

511

Participants

Timeline

Start Date

December 27, 2010

Primary Completion Date

May 19, 2016

Study Completion Date

May 19, 2016

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Vidaza®

The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.

Trial Locations (48)

431-796

Hallym University Sacred Heart Hospital, Anyang

420-853

Soon Chun Hyang University Hospital Bucheon, Bucheon-si

602-030

Kosin University Gospel Hospital, Busan

602-715

Dong-a University Medical Center, Busan

602-739

Pusan National University Hospital, Busan

614-735

Inje University Busan Paik Hospital, Busan

Inje University Haeundae Paik Hospital, Busan

619-953

Dongnam Inst. of Radiological & Medical Science, Busan

330-721

Soon Chun Hyang University Hospital Cheonan, Cheonan

138-736

Chungbuk National University Hospital, Cheongju-si

Asan Medical Center, Seoul

700-712

Keimyung University Dongsan Hospital, Daegu

Kyungpook National University Hospital, Daegu

701-010

Daegu Fatima Hospita, Daegu

705-030

Yeungnam University Medical Center, Daegu

705-034

Daegu Catholic University Medical Center, Daegu

301-721

Chungnam National University Hospital, Daejeon

302-799

Eulji University Hospital - Daejeon, Daejeon

410-773

Dongguk University Ilsan Hospital, Goyang

411-706

Inje University Ilsan Paik Hospital, Goyang

411-719

National Health Insurance Service Ilsan Hospital, Goyang

501-717

Chosun University Hospital, Gwangju

780-350

Dongguk University Gyeongju Hospital, Gyeongju

519-809

Hwasun Chonnam National University Hospital, Hwasun-gun

570-711

Wonkwang University Hospital, Iksan

400-711

Inha University Hospital, Incheon

405-760

Gacheon University Gil Hospital, Incheon

561-712

Chonbuk National University Hospital, Jeonju

660-702

Gyeongsang National University Hospital, Jinju

100-032

Inje University Seoul Paik Hospital, Seoul

110-744

Seoul National University Hospital, Seoul

120-752

Severance Hospital, Seoul

130-702

Kyunghee University Medical Center, Seoul

131-865

Seoul Medical Center, Seoul

135-710

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

136-705

Korea University Anam Hospital, Seoul

137-701

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

139-706

Korea Cancer Center Hospital, Seoul

139-707

Inje University Sanggye Paik Hospital, Seoul

143-729

Konkuk University Hospital, Seoul

152-703

Korea University Guro Hospital, Seoul

156-707

Boramae Medical Center, Seoul

156-755

Chung-ang University Hospital, Seoul

158-710

Ewha Womans University Mokdong Hospital, Seoul

442-723

The Catholic University of Korea, St. Vicent's Hospital, Suwon

443-721

Ajou University Medical Center, Suwon

682-714

Ulsan University Hospital, Ulsan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02137629 - Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea | Biotech Hunter | Biotech Hunter